Business Context and Reporting Period
Company: Grifols, S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Second Quarter and First Half ended June 30, 2024
Filing Date: July 30, 2024
Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, reported solid financial results for the first half of 2024, driven by a strong second quarter. The company reaffirmed its full-year 2024 guidance. Key strategic developments include the completion of the sale of a 20% stake in Shanghai RAAS (SRAAS) to Haier Group for approximately EUR 1.6 billion and a leadership transition with Nacho Abia assuming the role of CEO.
Key Financial Metrics
| Metric | Q2 2024 | H1 2024 | H1 2023 (Restated) |
|---|---|---|---|
| Total Revenue (Constant Currency) | EUR 1,818 million (+9.3% cc) | EUR 3,444 million (+7.5% cc) | EUR 3,225 million |
| Adjusted EBITDA | EUR 441 million (24.2% margin) | EUR 791 million (23.0% margin) | EUR 647 million |
| Reported Net Profit | EUR 15 million | EUR 36 million | (EUR 70 million) |
| Net Profit (Excl. One-offs) | EUR 105 million | EUR 152 million | EUR 36 million |
| Free Cash Flow | EUR 57 million | (EUR 196 million) | (EUR 253 million) |
| Leverage Ratio (Credit Facility) | 5.5x | 5.5x | 6.3x (FY23) |
| Net Financial Debt (Credit Facility) | EUR 8,262 million | EUR 8,262 million | EUR 9,416 million (Q4'23) |
| Liquidity (Excl. SRAAS proceeds) | EUR 915 million | EUR 915 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 7.5% at constant currency (cc) in H1 2024, accelerating to 9.3% cc in Q2. Growth was broad-based across all business units.
- Profitability: Reported net profit turned positive in H1 2024 (EUR 36 million) compared to a loss of EUR 70 million in H1 2023. Adjusted EBITDA grew 24.1% cc in H1 2024.
- Cash Flow: The company generated positive free cash flow of EUR 57 million in Q2 2024, a significant sequential improvement driven by working capital optimization (inventory, receivables, and payables).
- Deleveraging: The leverage ratio declined to 5.5x from 6.3x in Q4 2023, primarily due to the EUR 1.6 billion cash inflow from the SRAAS divestment and EBITDA improvement.
- Segment Performance:
- Biopharma: +8.9% cc in H1 2024. Immunoglobulin franchise grew 13.1% cc, driven by Xembify (SCIG) which surged nearly 60% cc. Albumin grew 9.6% cc.
- Diagnostic: +1.9% cc like-for-like in H1 2024, driven by Blood Typing Solutions (+14.0% cc).
- Bio Supplies: +32.6% cc in H1 2024.
Guidance, Outlook, and Risks
Guidance and Outlook
Management reaffirmed its full-year 2024 guidance:
- Total Revenue Growth: 7%+ (constant currency).
- Biopharma Revenue Growth: 8-10% (constant currency).
- Adjusted EBITDA: EUR 1,800 million+.
- Adjusted EBITDA Margin: 25-26%.
- Leverage Target: The company aims to reduce the leverage ratio to 4.5x by the end of 2024.
Management expects further margin expansion in H2 2024 due to the lagged impact of Cost Per Liter (CPL) reductions and operational leverage.
Risks and Contingencies
- Potential Takeover: On July 7, 2024, the Board analyzed a request from family shareholders and Brookfield Capital Partners regarding a potential joint tender offer for the entire share capital of Grifols. No agreement on terms exists yet, and there is no guarantee a tender offer will be made.
- Debt Covenants: Financing contracts include change-of-control clauses that could trigger early termination if a takeover occurs.
- Legal Proceedings: Ongoing litigation includes a patent dispute with Abbott Laboratories (trial expected late 2024/early 2025) and a settled wage and hour class action in California.
- Operational: Alpha-1 and Specialty proteins were flat in H1 2024 due to a strategic switch of the specialty pharma partner in the U.S.
Investor Verification Checklist
- SRAAS Transaction Impact: Verify the allocation of the EUR 1.6 billion proceeds toward debt reduction (Senior Secured Notes and Term Loan B) and the terms of the extended albumin distribution agreement with Haier.
- Working Capital Sustainability: Assess whether the significant Q2 improvement in free cash flow (driven by inventory and receivables optimization) is sustainable into H2.
- Cost Per Liter (CPL) Trends: Monitor the stabilization of CPL and its lagged impact on gross margins in the second half of the year.
- Takeover Bid Status: Track developments regarding the potential tender offer by Brookfield and family shareholders and its potential impact on debt covenants and executive compensation.
- Restated Comparatives: Note that H1 2023 figures have been restated due to accounting corrections regarding the Biotek America joint operation and SRAAS equity accounting; ensure comparisons use the restated figures.